Avoro Capital Advisors LLC
Emerging managerSEC-registered investment adviser.
- Website
- HTTP://www.avorocapital.com
- HQ
- NY
Avoro Capital Advisors is a global life sciences investment firm that supports emerging biotechnology companies. Its managing partner is Dr. Behzad Aghazadeh, and the firm's portfolio includes a long list of biotech and pharma companies, including Ethyreal Bio, Ottimo Pharma, and Hemab.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | None |
| Sectors | Biotech | Not enough dated deals | None |
| Regions | Global | Not enough dated deals | None |
Says: what the firm's funds state. Does: from 3 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2020 | 1 | Biotech, Healthtech |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Avoro Ventures Fund II L.P. | approx. 2026 | Not reported | Raising |
| Avoro Ventures Fund L.P. | 2021 | $178.42M (Form D) | Follow-ons only |
03 · People across funds
- Behzad Aghazadeh, Principal
Avoro Ventures Fund II L.P. (Named on Form D); Avoro Ventures Fund L.P. (Named on Form D)
- Neil Cammarosano, CFO of Avoro Ventures LLC
Avoro Ventures Fund II L.P. (Named on Form D)
- Scott Epstein, COO and CCO of Avoro Ventures LLC
Avoro Ventures Fund II L.P. (Named on Form D); Avoro Ventures Fund L.P. (Named on Form D)
04 · Recent deals
- Jun 16, 2026Ethyreal BioStage unknownFirmsource
- Jun 16, 2026Ethyreal BioSeries BFirmsource
- Dec 19, 2024Ottimo PharmaSeries AFirmsource
- Sep 23, 2024Vicebio LtdSeries BAvoro Ventures Fund L.P.source
05 · Latest from the firm
- Investment2026 | Avoro Capital AdvisorsJun 16, 2026
- InvestmentEthyreal Bio Antibody for Thyroid Eye Disease and Graves’ DiseaseJun 16, 2026
- Investment2024 | Avoro Capital AdvisorsDec 19, 2024
- InvestmentOttimo Pharma Raises over $140 Million in Series A Financing | Avoro Capital AdvisorsDec 19, 2024
06 · Sources
- HTTP://www.avorocapital.com
- https://avorocapital.com/contact/
- https://avorocapital.com/investments/
- https://avorocapital.com/news/
- https://avorocapital.com/news/ottimo-pharma-raises-over-140-million-in-series-a-financing/
- https://avorocapital.com/news/2026/
- https://avorocapital.com/team/
- https://avorocapital.com/
- https://avorocapital.com/news/2024/
- https://avorocapital.com/news/ethyreal-bio-emerges-from-stealth-with-101-million-in-financing-to-advance-ethy-001-a-potentially-best-in-class-anti-tshr-antibody-for-thyroid-eye-disease-and-graves-disease/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 25, 2026